Beacon Biosignals raises $97 million to expand brain monitoring
Updated
Updated · MIT News · May 1
Beacon Biosignals raises $97 million to expand brain monitoring
4 articles · Updated · MIT News · May 1
The funding follows last year's acquisition of a US at-home sleep apnea testing company serving more than 100,000 patients annually.
Founded in 2019 by Jake Donoghue and Jarrett Revels, Beacon makes an FDA-cleared home EEG headband already used in more than 40 clinical trials worldwide.
The company says its sleep-based brain data and machine-learning platform could improve diagnostics, track disease progression and support earlier detection of disorders including Alzheimer's, Parkinson's, depression and schizophrenia.
With a $132M war chest, how will Beacon Biosignals navigate the ethical maze of owning longitudinal brain data for millions of people?
As AI analyzes our sleep to predict brain disease, what happens when it finds a problem that medicine cannot yet solve?
Can a six-electrode home headband truly replace lab-grade diagnostics for complex conditions like schizophrenia and dementia?